Anti-CD20 mAbs were originally created to treat B cell proliferative diseases such as non-Hodgkin's lymphoma and chronic lymphocytic leukemia, but they have since been used to treat autoimmune ...

The FDA has extended its review of Novartis’ potential multiple sclerosis drug ofatumumab, pushing back a decision on the repurposed cancer drug until September this year. Ofatumumab could ...

Novartis’ cancer therapy ofatumumab has moved closer to its second life as a treatment for multiple sclerosis, with a regulatory decision in the US due in June and in Europe in the first half of ...